1. Home
  2. DFLI vs NXTC Comparison

DFLI vs NXTC Comparison

Compare DFLI & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dragonfly Energy Holdings Corp. (NV)

DFLI

Dragonfly Energy Holdings Corp. (NV)

HOLD

Current Price

$1.52

Market Cap

25.1M

Sector

Technology

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$5.40

Market Cap

24.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFLI
NXTC
Founded
2020
2015
Country
United States
United States
Employees
141
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
24.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
DFLI
NXTC
Price
$1.52
$5.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$3.25
$23.00
AVG Volume (30 Days)
297.5K
3.0M
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$51.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$1.55
52 Week High
$5.15
$15.74

Technical Indicators

Market Signals
Indicator
DFLI
NXTC
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
DFLI
NXTC

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: